Biosimilar Pipeline Report for 1H 2026

IPD Analytics has released its “Biosimilar Pipeline Report for 1H 2026”, offering an outlook on potential approvals and launches across the biosimilar landscape over the 2026–2030 horizon. With 16 biosimilars approved by the FDA in 2025, the report examines how biosimilars are supporting affordability while preserving access to clinically effective therapies.

The analysis highlights how increasing biosimilar utilization continues to drive declines in average sales prices (ASPs) for medical benefit drugs and lower net prices for pharmacy benefit products. The report also explores upcoming biosimilar candidates and recent updates to FDA interchangeability guidance, providing timely insights for managed care decision-making.

To stay current as the biosimilar market evolved, IPD subscribers can use this report alongside IPD’s Clinical Development Tracker within the Payer & Provider Insights platform, which delivers up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas.